Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Tonix Pharmaceuticals Holding Corp. reported revenue of $13M, up 29.8% year over year. Operating margin was -959.1% and net margin -946.2%, on a free-cash-flow margin of -787.5% with capital expenditure at 25.7% of revenue. Every figure is computed directly from TNXP's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $13M | -959.1% | -946.2% |
| FY2024 | $10M | -1354.3% | -1288.3% |
| FY2023 | $8M | -1523.9% | -1501.8% |
| FY2022 | n/a | n/a | n/a |
| FY2021 | n/a | n/a | n/a |
How does TNXP compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.